



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 99,274-C-DI)

In re Application of:

Ariel Boutaud

Serial No.: 10/603,725

Filed: June 25, 2003

For: Recombinant Laminn 5

Examiner: TBA

Art Unit: 1646

Confirmation No.: 6355

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


TRANSMITTAL LETTER

Sir:

1. We are transmitting herewith the attached papers for the above identified patent application:
 - ☒ Transmittal (in duplicate);
 - ☒ Information Disclosure Statements (IDS) and 1449 Forms in compliance with the continuing duty of candor as set forth in 37 CFR section 1.56 pursuant to 37 CFR section 1.98(d) (20 sheets);
 - ☒ Return Receipt Postcard.
2. With respect to fees:
 - ☒ No fee required.
3. **GENERAL AUTHORIZATION TO CHARGE OR CREDIT FEES:** Please charge any additional fees or credit overpayment to Deposit Account No. **13-2490**. A duplicate copy of this sheet is enclosed.
4. **CERTIFICATE OF MAILING BY "EXPRESS MAIL" UNDER 37 CFR § 1.10:** The undersigned hereby certifies that this Transmittal Letter and the papers, as described in paragraph 1 herein-above, are being deposited with the United States Postal Service with sufficient postage as "Express Mail Post Office to Addressee" in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 12th day of **January, 2005**. Express Mail No. **EV595490376US**.

By:

David S. Harper
Reg. No. 42,636



PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 99,274-C-DI)**

In re Application of:)	
)	Examiner: TBA
Ariel Boutaud)	
)	Group Art Unit: 1646
Serial No.: 10/603,725)	
)	Confirmation No.: 6355
Filed: June 25, 2003)	
)	
For: Recombinant Laminin 5)	

INFORMATION DISCLOSURE STATEMENT

**Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the references cited below are enclosed. These references are also listed on the enclosed PTO Form 1449.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative relevance between references, whether cited in this or prior statements. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

- ☒ This Information Disclosure Statement is being filed:
within three months of the filing date of a national application; within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or before the mailing date of a first Office Action on the merits. 37 C.F.R. §1.97 (b)
- ☐ **after** three months of the filing date of a national application, or the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or **after** the mailing date of a first Office Action on the merits, but **before** the mailing date of a Final Action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311 (whichever occurs first), and includes (37 C.F.R. § 1.97 (c):
- ☐ the Certification under 37 C.F.R. § 1.97(e) (see “Certification” below)

OR

- ☐ the fee of \$180.00 set forth in 37 C.F.R. § 1.17(p) (see “Fees” below).
- ☐ **after** a Final Action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311 (whichever occurs first), but before, or simultaneously with, the payment of the issue fee, and includes the Certification under 37 C.F.R. § 1.97(e) (see “Certification” below), and the Petition Fee set forth in 37 C.F.R. § 1.17(i) (see “Fees” and “Method of Payment of Fees” below). Applicants hereby petitions for consideration of the Information Disclosure Statement submitted herewith and the accompanying references in examination of the subject patent application.

CERTIFICATION

- ☐ The **undersigned** hereby certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.
- ☐ The **undersigned** hereby certifies that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

FEES

- ☒ No fee is owed by the applicant(s).
☐ The **IDS Fee of \$180.00** under 37 C.F.R. § 1.17(p) is enclosed herewith.
☐ The **Petition Fee of \$130.00** set forth in 37 C.F.R. § 1.17(i) is enclosed herewith.

METHOD OF PAYMENT OF FEES

- ☐ Attached is a check in the amount of \$180.00.
☐ Charge Deposit Account No. 13-2490 in the amount of \$. (A duplicate copy of this communication is enclosed for that purpose.)

Please charge any underpayment or credit any overpayment in connection with this communication to Deposit Account No. 13-2490. A duplicate copy of this communication is enclosed for this purpose.

CERTIFICATE OF MAILING AS "EXPRESS MAIL" (37 CFR 1.10) I hereby certify that this correspondence and all attached paper(s) or fee(s) is being deposited with sufficient postage, with the United States Postal Service as EXPRESS MAIL POST OFFICE TO ADDRESSEE in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 with sufficient postage, on this 12th Day of January, 2005. under Express Mail Certificate No. **EV595490376US**.

Date: 1-12-05

Respectfully submitted,



David S. Harper
Registration No. 42,636

Telephone: 312-913-0001
Facsimile: 312-913-0002

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive
Chicago, IL 60606

U.S. Patent Documents

1. Peter Yurchenco, U.S. Patent No. 6,632,790, Issued on October 14, 2003.
2. Jarrko Kortessmaa, et al., U.S. Patent No. 6,638,907, Issued on October 28, 2003.

Other Documents


3. Eble, et al., (1998), Biochemistry, Vol: 37 (31), pp. 10945-10955.
4. Ueda, E., (1997), Direct Submission, Accession No. D3776.

Date: _____

1-12-05

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff

By: _____


David S. Harper
Reg. No. 42,636

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.


99,274-C-DI

Serial No.

10/603,725

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)



Applicant:

Ariel Boutaud

Filing Date:

June 25, 2003

Group:

1646

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	1.	6,632,790	10-14-03	Peter Yurchenco			4-28-00
	2.	6,638,907	10-28-03	Jarrko Kortessmaa, et al.			4-28-00

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

3.	Eble, et al., (1998), Biochemistry, Vol: 37 (31), pp. 10945-10955.
4.	Ueda, E., (1997), Direct Submission, Accession No. D3776.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.



PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 99,274-C-DI)**

In re Application of:)	
)	Examiner: TBA
Ariel Boutaud)	
)	Group Art Unit: 1646
Serial No.: 10/603,725)	
)	Confirmation No.: 6355
Filed: June 25, 2003)	
)	
For: Recombinant Laminin 5)	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

**Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Pursuant to 37 C.F.R. §1.98(d), copies of references numbered 1-10 are not provided herewith, since they were previously filed in the parent application serial No. 09/560,385.

Applicants do not believe any fee is due with this submission. If this belief be in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned attorney by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

- ☒ This Information Disclosure Statement is being filed:
within three months of the filing date of a national application; within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or before the mailing date of a first Office Action on the merits. 37 C.F.R. § 1.97 (b)
- ☐ **after** three months of the filing date of a national application, or the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or **after** the mailing date of a first Office Action on the merits, but **before** the mailing date of a Final Action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311 (whichever occurs first), and includes (37 C.F.R. § 1.97 (c):

☐ the Certification under 37 C.F.R. § 1.97(e) (see “Certification” below)

OR

- ☐ the fee of \$180.00 set forth in 37 C.F.R. § 1.17(p) (see “Fees” below).
- ☐ **after** a Final Action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311 (whichever occurs first), but before, or simultaneously with, the payment of the issue fee, and includes the Certification under 37 C.F.R. § 1.97(e) (see “Certification” below), and the Petition Fee set forth in 37 C.F.R. § 1.17(i) (see “Fees” and “Method of Payment of Fees” below). Applicants hereby petitions for consideration of the Information Disclosure Statement submitted herewith and the accompanying references in examination of the subject patent application.

CERTIFICATION

- ☐ The **undersigned** hereby certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.
- ☐ The **undersigned** hereby certifies that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

FEES

- ☒ No fee is owed by the applicant(s).
☐ The **IDS Fee of \$180.00** under 37 C.F.R. § 1.17(p) is enclosed herewith.
☐ The **Petition Fee of \$130.00** set forth in 37 C.F.R. § 1.17(i) is enclosed herewith.

METHOD OF PAYMENT OF FEES

- ☐ Attached is a check in the amount of \$180.00.
☐ Charge Deposit Account No. 13-2490 in the amount of \$. (A duplicate copy of this communication is enclosed for that purpose.)

Please charge any underpayment or credit any overpayment in connection with this communication to Deposit Account No. 13-2490. A duplicate copy of this communication is enclosed for this purpose.

Foreign Patent Documents:

- | | | |
|----------------------------|-------------|------------------|
| 1. Burgeson, R.E., et al., | WO 94/05316 | 17-March-1994 |
| 2. Burgeson, R.E., et al., | WO 95/11972 | 04-May-1995 |
| 3. Quaranta, V., et al., | WO 95/13103 | 18-May-1995 |
| 4. Tryggvason, K. | WO 96/10646 | 11-April-1996 |
| 5. Halberstadt, C. | WO 97/12961 | 10-April-1997 |
| 6. Halberstadt, C. | WO 97/36621 | 09-October-1997 |
| 7. Fitchmun, M. | WO 97/47652 | 18-December-1997 |
| 8. Burgeson, R.E., | WO 97/48415 | 24-December-1997 |
| 9. Kato, S., et al., | WO 98/11217 | 19-March-1998 |

Article References:

10. Vailly, J., et al., *Gene Ther.*, 1998; 5: 1322-1332.


Date: _____

1-12-05

Respectfully submitted,



David S. Harper
Registration No. 42,636

FORM PTO-1449 (Rev. 2-32)	U. S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
99,274-C-DI		10/603,725	
Applicant: Ariel Boutaud, et al.			
 INFORMATION DISCLOSURE STATEMENT BY APPLICANT -SUPPLEMENTAL-	Filing Date:	Group:	
	June 25, 2003	1646	

U. S. PATENT DOCUMENTS

	Examiner Initials	Document Number	Date	Name	Class	Subclass
--	----------------------	-----------------	------	------	-------	----------

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
1.		WO 94/05316	17-March-1994	PCT				
2.		WO 95/11972	04-May-1995	PCT				
3.		WO 95/13103	18-May-1995	PCT				
4.		WO 96/10646	11-April-1996	PCT				
5.		WO 97/12961	10-April-1997	PCT				
6.		WO 97/36621	09-October-1997	PCT				
7.		WO 97/47652	18-December-1997	PCT				
8.		WO 97/48415	24-December-1997	PCT				
9.		WO 98/11217	19-March-1998	PCT				

OTHER DOCUMENTS

10.	Vailly, J., et al., <i>Gene Ther.</i> , 1998; 5: 1322-1332.
-----	---

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered. Include copy of this form with next communication.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 99,274-C-DI)

In re Application of:

Ariel Boutaud

Serial No.: 10/603,725

Filed: June 25, 2003

For: Recombinant Laminin 5

Examiner: TBA

Group Art Unit: 1646

Confirmation No.: 6355

INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Pursuant to 37 C.F.R. §1.98(d), copies of references numbered 1-87 are not provided herewith, since they were previously filed in the parent application serial No. 09/560,385.

Applicants do not believe any fee is due with this submission. If this belief be in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned attorney by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.



This Information Disclosure Statement is being filed:

within three months of the filing date of a national application; within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or before the mailing date of a first Office Action on the merits. 37 C.F.R. §1.97 (b)



after three months of the filing date of a national application, or the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or **after** the mailing date of a first Office Action on the merits, but **before** the mailing date of a Final Action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311 (whichever occurs first), and includes (37 C.F.R. § 1.97 (c):



the Certification under 37 C.F.R. § 1.97(e) (see “Certification” below)

OR



the fee of \$180.00 set forth in 37 C.F.R. § 1.17(p) (see “Fees” below).



after a Final Action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311 (whichever occurs first), but before, or simultaneously with, the payment of the issue fee, and includes the Certification under 37 C.F.R. § 1.97(e) (see “Certification” below), and the Petition Fee set forth in 37 C.F.R. § 1.17(i) (see “Fees” and “Method of Payment of Fees” below). Applicants hereby petitions for consideration of the Information Disclosure Statement submitted herewith and the accompanying references in examination of the subject patent application.

CERTIFICATION



The **undersigned** hereby certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.



The **undersigned** hereby certifies that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

FEES

- ☒ No fee is owed by the applicant(s).
☐ The **IDS Fee of \$180.00** under 37 C.F.R. § 1.17(p) is enclosed herewith.
☐ The **Petition Fee of \$130.00** set forth in 37 C.F.R. § 1.17(i) is enclosed herewith.

METHOD OF PAYMENT OF FEES

- ☐ Attached is a check in the amount of \$180.00.
☐ Charge Deposit Account No. 13-2490 in the amount of \$. (A duplicate copy of this communication is enclosed for that purpose.)

Please charge any underpayment or credit any overpayment in connection with this communication to Deposit Account No. 13-2490. A duplicate copy of this communication is enclosed for this purpose.

U.S. Patent Documents:

- | | |
|---|-------------------------------|
| 1. Nichols, U.S. Patent No.: 5,019,087 | Published: May 28, 1991 |
| 2. Potter, et al., U.S. Patent No.: 5,229,365 | Published: July 20, 1993 |
| 3. Quaranta, et al., U.S. Patent No.: 5,422,264 | Published: June 6, 1995 |
| 4. Engvall, et al., U.S. Patent No.: 5,444,158 | Published: August 22, 1995 |
| 5. Quaranta, et al., U.S. Patent No.: 5,510,263 | Published: April 23, 1996 |
| 6. Jones, U.S. Patent No.: 5,541,106 | Published: July 30, 1996 |
| 7. Jones, et al., U.S. Patent No.: 5,585,267 | Published: December 17, 1996 |
| 8. Engvall, et al., U.S. Patent No.: 5,624,905 | Published: April 29, 1997 |
| 9. Quaranta, et al., U.S. Patent No.: 5,658,789 | Published: August 19, 1997 |
| 10. Halberstadt, et al., U.S. Patent No.: 5,672,361 | Published: September 30, 1997 |
| 11. Halberstadt, et al., U.S. Patent No.: 5,681,587 | Published: October 28, 1997 |
| 12. Burgeson, et al., U.S. Patent No.: 5,770,562 | Published: June 23, 1998 |
| 13. Campbell, et al., U.S. Patent No.: 5,863,743 | Published: January 26, 1999 |
| 14. Engvall, et al., U.S. Patent No.: 5,872,231 | Published: February 16, 1999 |

Foreign Patent Documents:

15. Drohan, et al., European Patent No.: EP0204302, Published: December 10, 1986

Article References:


16. Altschul, et al., *J. Mol. Biol.*, **215**, 1990, pp. 403-410.
17. Altschul, et al., *Nucleic Acids. Res.*, **25**, 1997, pp. 3389-3402.
18. Assoain, R. K. and Marcantonio, E. E., *J. Clin. Invest.*, **100**(11), 1997, pp. S15-S18.
19. Aumailley, M. and Krieg, T., *J. Invest. Dermatol.*, **106**, 1996, pp. 209-214.
20. Aumailley et al., In The Laminins, Timpl and Ekblom, eds., Harwood Academic Publishers, Amsterdam (1996), pp. 127-158.
21. Bailey, S. B., et al., *J. Neurocytology*, **22**, 1993, pp. 176-184.
22. Baker et al., *Exp. Cell Res.*, **228**(2), Nov 1, 1996, pp. 262-270.
23. Bates, C. A. and Meyer, R. L., *Dev. Biol.*, **181**, 1997, pp. 91-101.
24. Bonfil et al., *Int. J. Cancer*, **58**, 1994, pp. 233-239.
25. Bowie, J. U. et al., *Science*, **247**, 1990pp.1306-1310.
26. Brown, J. C., et al., *J. Cell Sci.*, **107**, 1994, pp. 329-338.
27. Cheng, Y.-S., et al., *J. Biol. Chem.*, **272**(50), 1997, pp. 31525-31532.
28. Cleland et al., *Crit. Rev. Therapeutic Drug Carrier Systems*, **10**, 1993, pp. 307-377.
29. Colognato, H., et al., *J. Cell Biol.*, **145**(3), 1999, pp. 619-631.
30. Cunningham and Wells, *Science*, **244**, 1989, pp. 1081-1085.
31. Dobeli, et al., *J. Biotechnology*, **7**, 1988pp.199-216.
32. Donaldson, D. J. and Mahan, J. T., *Cell Tissue Res.*, **235**, 1984, pp. 221-224.
33. El-Ghannam, A., et al., *J. Biomed. Mater. Res.*, **41**(4), 1998, pp. 30-40.
34. Ervasti and Campbell, *J. Cell Biol.*, **122**(4), 1993, pp. 809-823.
35. Folkman et al., *Adv. Cancer Res.*, **43**, 1985, pp. 175-203.
36. Gagnoux-Palacios, L., et al., *J. Biol. Chem.*, **271**(31), 1996, pp. 18437-18444.
37. Galliano et al., *J. Biol. Chem.*, **270**, 1995, pp. 21820-221826.
38. Gayle, et al., *J. Biol. Chem.*, **268**, 1993pp. 22105-22111.
39. Gerecke et al., *J. Biol. Chem.*, **269**, 1994, pp. 11073-11080.
40. Giannelli, G., et al., *Science*, **277**, 1997, pp. 225-228.
41. Glukhova, M., et al., *Dev. Biol.*, **157**, 1993, pp. 437-447.
42. Goldfinger et al., *J. Cell Sci.*, **112**(Pt. 16), 1999, pp. 2615-2629.

43. Goldfinger, L. E., et al., *J. Cell Biol.*, **141**(1), 1998, pp. 255-265.
44. Gonzales et al., *Mol. Biol. Cell.*, **10**(2), Feb, 1999, pp. 259-270.
45. Grant, D. S. and Kleinman, H. K., *Regulation of Angiogenesis*, Goldberg I.D., and Rosen, E.M., eds., Birkhauser Verlag, Basel, Switzerland, 1997, pp. 317-333.
46. Hedin, U., et al., *J. Cell Biol.*, **107**, 1988, pp. 307-319.
47. Hormia, M., et al., *J. Dent. Res.*, **77**(7), 1998, pp. 1479-1485.
48. Hormia et al., *J. Invest. Dermatol.* 1995 Oct. **105**(4): pp. 557-561.
49. Iivananinen et al., *J. Biol. Chem.*, **274**, 1999, pp. 14107-14111.
50. Kallunki et al., *J. Cell Biol.*, **119**, 1992, pp. 679-693.
51. Kamiguchi, H., et al., *Annu. Rev. Neurosci.*, **21**, 1998, pp. 97-125.
52. Karlin and Altschul, *Proc. Natl. Acad. Sci. USA*, **87**, 1990, pp. 2264-2268.
53. Karlin and Altschul, *Proc. Natl. Acad. Sci. USA*, **90**, 1993, pp. 5873-5877.
54. Koch, M., et al., *J. Cell Biol.*, **145**(2), 1999, pp. 605-617.
55. Lotz, M. M., et al., *Am. J. Path.*, **150**(2), 1997, pp. 747-759.
56. Malinda, K. M. and Kleinman, H. K., *Int. J. Biochem. Cell Biol.*, **28**(9), 1996, pp. 957-959.
57. Malinda, K. M., et al., *FASEB J.*, **13**, 1999, pp. 53-62.
58. Matsui, C., et al., *J. Biol. Chem.*, **270**(40), 1995, pp. 23496-23503.
59. Miner, J. H. and Patton, B. L., *Int. J. Biochem. Cell Biol.*, **31**, 1999, pp. 811-816.
60. Mullen et al., *J. Periodontal. Res.*, **34**(1), Jan, 1999, pp. 16-24.
61. Nicosia, R. F., et al., *Dev. Biol.*, **164**, 1994, pp. 197-206.
62. Nomizu, M., et al., *J. Biol. Chem.*, **272**(51), 1997, pp. 32198-32205.
63. Olsen, D., et al., *Lab. Invest.*, **60**(6), 1989, pp. 772-782.
64. O'Toole, E. A., et al., *Exp. Cell Res.*, **233**, 1997, pp. 330-339.
65. Patton, B. L., et al., *J. Cell Biol.*, **139**(6), 1997, pp. 1506-1521.
66. Patton, B. L., et al., *Neuromusc. Disord.*, **9**, 1999, pp. 423-433.
67. Pinckard et al., *Clin. Exp. Immunol.*, **2**, 1967, pp. 331-340.
68. Ponce, M. L., et al., *Circ. Res.*, **84**, 1999, pp. 688-694.
69. Qin and Kurpakus, *Exp. Eye Res.*, **66**(5), May, 1998, pp. 569-579.
70. Richards, D. W., et al., *J. Dent. Res.*, **75**(7), 1996, pp. 1512-1517.
71. Robbins et al., *Diabetes*, **36**, 1987, pp. 838-845.

72. Ron, et al., *J. Biol. Chem.*, **268**, 1993, pp. 2984-2988.
73. Rousselle, P., et al., *JBC*, **270**(23), 1995, pp. 13766-13770.
74. Ryan, M., et al., *J. Cell Biol.*, **145**(6), 1999, pp. 1309-1323.
75. Ryan, M. C. and Christiano, A. M., *Matrix Biol.*, **15**, 1996, pp. 369-381.
76. Sato, K., et al., *Exp. Cell Res.*, **247**, 1999, pp. 451-460.
77. Sugiyama et al., *Eur. J. Biochem.*, **228**, 1995, pp. 120-128.
78. Takeda, A., et al., *J. Invest. Dermatology*, **113**, 1999, pp. 38-42.
79. Thyberg, J., et al., *J. Histochem. Cytochem.*, **45**(6), 1997, pp. 837-846.
80. Thyberg, J. and Hultgårdh-Nilsson, A., *Cell Tissue Res.*, **276**, 1994, pp. 263-271.
81. Todorov et al., *Transplant. Proc.*, **30**(2), Mar, 1998, pp. 455.
82. Tsunenaga et al., *Matrix Biol.* **17**(8-9), 1998, pp. 603-613.
83. Vivinus-Nebot, M., et al., *J. Cell Biol.*, **144**, 1999, pp. 563-574.
84. Wewer, U. M. and Engvall, E., *Neuromusc. Disord.*, **6**, 1996, pp. 409-418.
85. Yoshida et al., *Cell Tissue Res.*, **292**(1), Apr, 1998, pp. 143-149.
86. Yurchenco, P. D., et al., *Proc. Natl. Acad. Sci. USA*, **94**, 1997, pp. 10189-10194.

Date: 1-12-05

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff

By: 
David S. Harper
Reg. No. 42,636

FORM PTO-1449
(Rev. 2-32)U. S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

99,274-C-DI

Serial No.

10/603,725

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT


Applicant: Ariel Boutaud, et al.

Filing Date:

June 25, 2003

Group:

1646



U. S. PATENT DOCUMENTS

	Examiner Initials	Document Number							Date	Name	Class	Subclass
1.		5	0	1	9	0	8	7	05-28-91	Nichols		
2.		5	2	2	9	3	6	5	07-20-93	Potter, et al.		
3.		5	4	2	2	2	6	4	06-06-95	Quaranta, et al.		
4.		5	4	4	4	1	5	8	08-22-95	Engvall, et al.		
5.		5	5	1	0	2	6	3	04-23-96	Quaranta, et al.		
6.		5	5	4	1	1	0	6	07-30-96	Jones		
7.		5	5	8	5	2	6	7	12-17-96	Jones, et al.		
8.		5	6	2	4	9	0	5	04-29-97	Engvall, et al.		
9.		5	6	5	8	7	8	9	08-19-97	Quaranta, et al.		
10.		5	6	7	2	3	6	1	09-30-97	Halberstadt, et al.		
11.		5	6	8	1	5	8	7	10-28-97	Halberstadt, et al.		
12.		5	7	7	0	5	6	2	06-23-98	Burgeson et al.		
13.		5	8	6	3	7	4	3	01-26-99	Campbell, et al.,		
14.		5	8	7	2	2	3	1	02-16-99	Engvall, et al.		

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
15.		EP0204302	December 10, 1986		A2			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) U. S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Atty. Docket No. 99,274-C-DI	Serial No. 10/603,725
	Applicant: Ariel Boutaud, et al.	
	Filing Date: June 25, 2003	Group: 1646

U. S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation
					Yes No

OTHER DOCUMENTS

16.	Altschul, et al., <i>J. Mol. Biol.</i> , 215 , 1990, pp. 403-410.
17.	Altschul, et al., <i>Nucleic Acids. Res.</i> , 25 , 1997, pp. 3389-3402.
18.	Assoain, R. K. and Marcantonio, E. E., <i>J. Clin. Invest.</i> , 100 (11), 1997, pp. S15-S18.
19.	Aumailley, M. and Krieg, T., <i>J. Invest. Dermatol.</i> , 106 , 1996, pp. 209-214.
20.	Aumailley et al., In <i>The Laminins</i> , Timpl and Ekblom, eds., Harwood Academic Publishers, Amsterdam (1996), pp. 127-158.
21.	Bailey, S. B., et al., <i>J. Neurocytology</i> , 22 , 1993, pp. 176-184.
22.	Baker et al., <i>Exp. Cell Res.</i> , 228 (2), Nov 1, 1996, pp. 262-270.
23.	Bates, C. A. and Meyer, R. L., <i>Dev. Biol.</i> , 181 , 1997, pp. 91-101.
24.	Bonfil et al., <i>Int. J. Cancer</i> , 58 , 1994, pp. 233-239.
25.	Bowie, J. U. et al., <i>Science</i> , 247 , 1990pp.1306-1310.
26.	Brown, J. C., et al., <i>J. Cell Sci.</i> , 107 , 1994, pp. 329-338.
27.	Cheng, Y.-S., et al., <i>J. Biol. Chem.</i> , 272 (50), 1997, pp. 31525-31532.
28.	Cleland et al., <i>Crit. Rev. Therapeutic Drug Carrier Systems</i> , 10 , 1993, pp. 307-377.
29.	Colognato, H., et al., <i>J. Cell Biol.</i> , 145 (3), 1999, pp. 619-631.
30.	Cunningham and Wells, <i>Science</i> , 244 , 1989, pp. 1081-1085.
31.	Dobeli, et al., <i>J. Biotechnology</i> , 7 , 1988pp.199-216.
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)U. S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

99,274-C-DI

Serial No.

10/603,725

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Applicant: Ariel Boutaud, et al.

Filing Date:

June 25, 2003

Group:

1646

U. S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation	
					Yes	No

OTHER DOCUMENTS

32.	Donaldson, D. J. and Mahan, J. T., <i>Cell Tissue Res.</i> , 235, 1984, pp. 221-224.
33.	El-Ghannam, A., et al., <i>J. Biomed. Mater. Res.</i> , 41(4), 1998, pp. 30-40.
34.	Ervasti and Campbell, <i>J. Cell Biol.</i> , 122(4), 1993, pp. 809-823.
35.	Folkman et al., <i>Adv. Cancer Res.</i> , 43, 1985, pp. 175-203.
36.	Gagnoux-Palacios, L., et al., <i>J. Biol. Chem.</i> , 271(31), 1996, pp. 18437-18444.
37.	Galliano et al., <i>J. Biol. Chem.</i> , 270, 1995, pp. 21820-221826.
38.	Gayle, et al., <i>J. Biol. Chem.</i> , 268, 1993pp. 22105-22111.
39.	Gerecke et al., <i>J. Biol. Chem.</i> , 269, 1994, pp. 11073-11080.
40.	Giannelli, G., et al., <i>Science</i> , 277, 1997, pp. 225-228.
41.	Glukhova, M., et al., <i>Dev. Biol.</i> , 157, 1993, pp. 437-447.
42.	Goldfinger et al., <i>J. Cell Sci.</i> , 112(Pt. 16), 1999, pp. 2615-2629.
43.	Goldfinger, L. E., et al., <i>J. Cell Biol.</i> , 141(1), 1998, pp. 255-265.
44.	Gonzales et al., <i>Mol. Biol. Cell.</i> , 10(2), Feb, 1999, pp. 259-270.
45.	Grant, D. S. and Kleinman, H. K., <i>Regulation of Angiogenesis</i> , Goldberg I.D., and Rosen, E.M., eds., Birkhauser Verlag, Basel, Switzerland, 1997, pp. 317-333.
46.	Hedin, U., et al., <i>J. Cell Biol.</i> , 107, 1988, pp. 307-319.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U. S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 99,274-C-DI	Serial No. 10/603,725
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Ariel Boutaud, et al.	
		Filing Date: June 25, 2003	Group: 1646

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS

47.		Hormia, M., et al., <i>J. Dent. Res.</i> , 77(7), 1998, pp. 1479-1485.
48.		Hormia et al., <i>J. Invest. Dermatol.</i> 1995 Oct. 105(4): pp. 557-561.
49.		Iivananinen et al., <i>J. Biol. Chem.</i> , 274, 1999, pp. 14107-14111.
50.		Kallunki et al., <i>J. Cell Biol.</i> , 119, 1992, pp. 679-693.
51.		Kamiguchi, H., et al., <i>Annu. Rev. Neurosci.</i> , 21, 1998, pp. 97-125.
52.		Karlin and Altschul, <i>Proc. Natl. Acad. Sci. USA</i> , 87, 1990, pp. 2264-2268.
53.		Karlin and Altschul, <i>Proc. Natl. Acad. Sci. USA</i> , 90, 1993, pp. 5873-5877.
54.		Koch, M., et al., <i>J. Cell Biol.</i> , 145(2), 1999, pp. 605-617.
55.		Lotz, M. M., et al., <i>Am. J. Path.</i> , 150(2), 1997, pp. 747-759.
56.		Malinda, K. M. and Kleinman, H. K., <i>Int. J. Biochem. Cell Biol.</i> , 28(9), 1996, pp. 957-959.
57.		Malinda, K. M., et al., <i>FASEB J.</i> , 13, 1999, pp. 53-62.
58.		Matsui, C., et al., <i>J. Biol. Chem.</i> , 270(40), 1995, pp. 23496-23503.
59.		Miner, J. H. and Patton, B. L., <i>Int. J. Biochem. Cell Biol.</i> , 31, 1999, pp. 811-816.
60.		Mullen et al., <i>J. Periodontal. Res.</i> , 34(1), Jan, 1999, pp. 16-24.
61.		Nicosia, R. F., et al., <i>Dev. Biol.</i> , 164, 1994, pp. 197-206.
62.		Nomizu, M., et al., <i>J. Biol. Chem.</i> , 272(51), 1997, pp. 32198-32205.
63.		Olsen, D., et al., <i>Lab. Invest.</i> , 60(6), 1989, pp. 772-782.
64.		O'Toole, E. A., et al., <i>Exp. Cell Res.</i> , 233, 1997, pp. 330-339.
65.		Patton, B. L., et al., <i>J. Cell Biol.</i> , 139(6), 1997, pp. 1506-1521.
66.		Patton, B. L., et al., <i>Neuromusc. Disord.</i> , 9, 1999, pp. 423-433.
67.		Pinckard et al., <i>Clin. Exp. Immunol.</i> , 2, 1967, pp. 331-340.
68.		Ponce, M. L., et al., <i>Circ. Res.</i> , 84, 1999, pp. 688-694.
69.		Qin and Kurpakus, <i>Exp. Eye Res.</i> , 66(5), May, 1998, pp. 569-579.
70.		Richards, D. W., et al., <i>J. Dent. Res.</i> , 75(7), 1996, pp. 1512-1517.

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U. S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 99,274-C-DI	Serial No. 10/603,725
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Ariel Boutaud, et al.	
		Filing Date: June 25, 2003	Group: 1646

OTHER DOCUMENTS

71.	Robbins et al., <i>Diabetes</i> , 36, 1987, pp. 838-845.
72.	Ron, et al., <i>J. Biol. Chem.</i> , 268, 1993, pp. 2984-2988.
73.	Rousselle, P., et al., <i>JBC</i> , 270(23), 1995, pp. 13766-13770.
74.	Ryan, M., et al., <i>J. Cell Biol.</i> , 145(6), 1999, pp. 1309-1323.
75.	Ryan, M. C. and Christiano, A. M., <i>Matrix Biol.</i> , 15, 1996, pp. 369-381.
76.	Sato, K., et al., <i>Exp. Cell Res.</i> , 247, 1999, pp. 451-460.
77.	Sugiyama et al., <i>Eur. J. Biochem.</i> , 228, 1995, pp. 120-128.
78.	Takeda, A., et al., <i>J. Invest. Dermatology</i> , 113, 1999, pp. 38-42.
79.	Thyberg, J., et al., <i>J. Histochem. Cytochem.</i> , 45(6), 1997, pp. 837-846.
80.	Thyberg, J. and Hultgårdh-Nilsson, A., <i>Cell Tissue Res.</i> , 276, 1994, pp. 263-271.
81.	Todorov et al., <i>Transplant. Proc.</i> , 30(2), Mar, 1998, pp. 455.
82.	Tsunenaga et al., <i>Matrix Biol.</i> 17(8-9), 1998, pp. 603-613.
83.	Vivinus-Nebot, M., et al., <i>J. Cell Biol.</i> , 144, 1999, pp. 563-574.
84.	Wewer, U. M. and Engvall, E., <i>Neuromusc. Disord.</i> , 6, 1996, pp. 409-418.
85.	Yoshida et al., <i>Cell Tissue Res.</i> , 292(1), Apr, 1998, pp. 143-149.
86.	Yurchenco, P. D., et al., <i>Proc. Natl. Acad. Sci. USA</i> , 94, 1997, pp. 10189-10194.

Pending U.S. Patent Applications

87.	Kortesmaa, et al., Serial No. 09/561,818; Filed on April 28, 2000.		
<table border="1" style="width: 100%;"> <tr> <td style="width: 50%;">EXAMINER</td> <td style="width: 50%;">DATE CONSIDERED</td> </tr> </table>		EXAMINER	DATE CONSIDERED
EXAMINER	DATE CONSIDERED		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered. Include copy of this form with next communication.